These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 10546082)

  • 1. [Economic comparison of olanzapine versus haloperidol in treatment of schizophrenia in France].
    Le Pen C; Lilliu H; Allicar MP; Olivier V; Gregor KJ
    Encephale; 1999; 25(4):281-6. PubMed ID: 10546082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial.
    Hamilton SH; Revicki DA; Edgell ET; Genduso LA; Tollefson G
    Pharmacoeconomics; 1999 May; 15(5):469-80. PubMed ID: 10537964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
    Rosenheck R; Perlick D; Bingham S; Liu-Mares W; Collins J; Warren S; Leslie D; Allan E; Campbell EC; Caroff S; Corwin J; Davis L; Douyon R; Dunn L; Evans D; Frecska E; Grabowski J; Graeber D; Herz L; Kwon K; Lawson W; Mena F; Sheikh J; Smelson D; Smith-Gamble V;
    JAMA; 2003 Nov; 290(20):2693-702. PubMed ID: 14645311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia.
    Tunis SL; Johnstone BM; Gibson PJ; Loosbrock DL; Dulisse BK
    J Clin Psychiatry; 1999; 60 Suppl 19():38-45; discussion 46. PubMed ID: 10507279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia.
    Glazer WM; Johnstone BM
    J Clin Psychiatry; 1997; 58 Suppl 10():50-4. PubMed ID: 9265917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cost effectiveness analysis of olanzapine versus haloperidol in the treatment of schizophrenia++ in Spain].
    Sacristán JA; Gómez JC; Salvador-Carulla L
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1997; 25(4):225-34. PubMed ID: 9412161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olanzapine: an updated review of its use in the management of schizophrenia.
    Bhana N; Foster RH; Olney R; Plosker GL
    Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial.
    Gomez JC; Crawford AM
    J Clin Psychiatry; 2001; 62 Suppl 2():6-11. PubMed ID: 11232753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-effectiveness clinical decision analysis model for schizophrenia.
    Palmer CS; Revicki DA; Genduso LA; Hamilton SH; Brown RE
    Am J Manag Care; 1998 Mar; 4(3):345-55. PubMed ID: 10178497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol.
    Almond S; O'Donnell O
    Pharmacoeconomics; 2000 Apr; 17(4):383-9. PubMed ID: 10947493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
    Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME
    Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olanzapine versus haloperidol treatment in first-episode psychosis.
    Sanger TM; Lieberman JA; Tohen M; Grundy S; Beasley C; Tollefson GD
    Am J Psychiatry; 1999 Jan; 156(1):79-87. PubMed ID: 9892301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olanzapine. A pharmacoeconomic review of its use in schizophrenia.
    Foster RH; Goa KL
    Pharmacoeconomics; 1999 Jun; 15(6):611-40. PubMed ID: 10538333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.
    Tollefson GD; Sanger TM
    Am J Psychiatry; 1997 Apr; 154(4):466-74. PubMed ID: 9090332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand.
    Gureje O; Miles W; Keks N; Grainger D; Lambert T; McGrath J; Tran P; Catts S; Fraser A; Hustig H; Andersen S; Crawford AM
    Schizophr Res; 2003 Jun; 61(2-3):303-14. PubMed ID: 12729882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.
    Kinon BJ; Roychowdhury SM; Milton DR; Hill AL
    J Clin Psychiatry; 2001; 62 Suppl 2():17-21. PubMed ID: 11232746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol.
    Tunis SL; Croghan TW; Heilman DK; Johnstone BM; Obenchain RL
    Med Care; 1999 Jul; 37(7):678-91. PubMed ID: 10424639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample.
    Hamilton SH; Edgell ET; Revicki DA; Breier A
    Int Clin Psychopharmacol; 2000 Sep; 15(5):245-55. PubMed ID: 10993126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cost-effectiveness clinical decision analysis model for treatment of Schizophrenia.
    Palmer CS; Brunner E; Ruíz-Flores LG; Paez-Agraz F; Revicki DA
    Arch Med Res; 2002; 33(6):572-80. PubMed ID: 12505105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial.
    Ishigooka J; Inada T; Miura S
    Psychiatry Clin Neurosci; 2001 Aug; 55(4):403-14. PubMed ID: 11442893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.